To investigate whether treatment of melanoma cells with T-VEC could result in the release of potent stimuli that could activate the injected DC, we in vitro treated BDCA-1+/BDCA-3+ myDC with supernatant from melanoma cells treated with T-VEC. Here, CD1C is linked to melanoma.